Pharma
Curative Therapeutics

There are only a small number of diseases in which intervention at a single point, common across all patients, can sufficiently and persistently alter the system towards a healthy state. Most diseases consist of a complex set of dynamic failures from genetics and epigenetics to neural activity: these differ across patients, within patients and over time. Trials often fail because the models used to demonstrate effectiveness in preclinical studies don’t accurately reflect the underlying causes, which can vary substantially across diseases and patients, and endpoints in trials often measure symptoms.
Our approach to creating curative therapeutic companies focuses on four themes: effectively leveraging computational approaches to address complexity; developing therapeutics that can compute in-vivo and respond dynamically to the changing internal environment; creating better systems, models and analytics to support therapeutic discovery and development; and a focus on the root cause, including fixing and buffering molecular level damage, fixing broken or unhelpful messaging and signalling pathways, correcting errors at every level of gene expression and modifying the state of cells to drive regeneration.
Areas of venture creation:
Available opportunities
Our companies
Content

-
pharmaceuticals
-
Cystic Fibrosis
Creating Gene Therapies for Cystic Fibrosis
In this article, we outline how far gene therapies have come since they were first utilised in the early 1990s, how we're planning on using a promising approach to develop a curative therapy for Cystic Fibrosis, and how you can join us to make it a reality.

-
pharmaceuticals
-
Partnerships
Optimizing for Outcomes: how fresh perspectives can solve complex diseases
Using our methodology of venture creation, we're able to uncover novel therapeutics approaches in a disease area, that often haven't previously been considered. In this article, we explain how this works in practice, and how we've worked with two partners, the Children's Tumor Foundation and the Cystic Fibrosis Foundation, to uncover approaches within Neurofibromatosis and Cystic Fibrosis respectively.